A man's orgasms triggered flu-like symptoms and brain fog due to a rare condition called post-orgasmic illness syndrome .

Shares of Allakos (ALLK) are down 75% in pre-market trading after the company announced it will discontinue further clinical development of ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult ...

Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

could be stopped by omalizumab, an anti-IgE antibody,” Levi-Schaffer said. Maurer focused on mast cells, mastocytosis, pruritus, angioedema and atopic dermatitis. He also was an author on eight ...

FDA approval of two biosimilars to Prolia (denosumab) and a biosimilar to Xolair (omalizumab) are in the works, although none of them have PDUFA dates yet, according to AscellaHealth’s most recent ...

The key is a drug originally designed to treat asthma patients. “The way that omalizumab or Xolair works is that it binds to your allergy cells, and it takes it out of circulation,” Sindher said.

For a complete picture of Omalizumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here. Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled ...